Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Barlow, D.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barlow, D.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 12, 2479-2480, December 2001
© 2001 European Society of Human Reproduction and Embryology

EDITORIAL

Cost-effectiveness modelling

D.H. Barlow, Editor-in-Chief

In this issue of Human Reproduction we publish two papers on the cost-effectiveness of gonadotrophin therapies within IVF in the UK (Daya et al., 2001Go; Sykes et al., 2001Go). Cost-effectiveness issues are essentially a parochial activity since costing aspects are inevitably different in different health care systems, but although the detailed outcome of such an analysis is restricted to practice in one country, there are often insights of wider application as a result of the analysis and the methods used.

The central importance of cost-effectiveness . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
N. Gleicher, M. Vietzke, and A. Vidali
Bye-bye urinary gonadotrophins?: Recombinant FSH: A real progress in ovulation induction and IVF?
Hum. Reprod., March 1, 2003; 18(3): 476 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. Al-Inany, M. Aboulghar, R. Mansour, and G. Serour
Meta-analysis of recombinant versus urinary-derived FSH: an update
Hum. Reprod., February 1, 2003; 18(2): 305 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Balen
Bye-bye urinary gonadotrophins?: Is there a risk of prion disease after the administration of urinary-derived gonadotrophins?
Hum. Reprod., July 1, 2002; 17(7): 1676 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. Al-Inany and M. Afnan
Models of cost-effectiveness of recombinant FSH versus urinary FSH.
Hum. Reprod., June 1, 2002; 17(6): 1671 - 1673.
[Full Text] [PDF]